TIMOTHY L. MOORE
CIK 1669207 · Chief Technical Officer · last filed 2026-02-26
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$2.78M
Companies
5
Total Filings
34
Lifetime Open-Market Net
-$3.33M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| BLFS | Director | 44,943 | $36.47 | $1.64M | $0 | 7 | 2026-02-26 |
| CERS | Director | 205,073 | $2.85 | $584.5K | $32.2K | 14 | 2025-06-04 |
| ALLO | Chief Technical Officer | 250,713 | $2.23 | $559.1K | -$25.2K | 4 | 2025-02-05 |
| TIL | Chief Operating Officer | — | $7.39 | — | $0 | 1 | 2022-09-06 |
| Kite Pharma, Inc. (KITE) Delisted | EVP, Technical Operations | 45,661 | — | — | -$3.34M | 5 | 2017-09-27 |
Recent Filings · Page 3 of 4
34 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2020-09-08 | CERS | Exer (M) | +4,296 | $0 | EDGAR |
| 2020-06-05 | CERS | Grant (A) | — | $0 | EDGAR |
| 2020-02-13 | CERS | Buy (P) | +3,614 | $17.2K | EDGAR |
| 2020-02-13 | CERS | Buy (P) | — | $0 | EDGAR |
| 2020-02-03 | CERS | Buy (P) | +3,614 | $15.0K | EDGAR |
| 2019-09-10 | CERS | Exer (M) | +4,297 | $0 | EDGAR |
| 2019-06-07 | CERS | Grant (A) | — | $0 | EDGAR |
| 2018-09-07 | CERS | Grant (A) | — | $0 | EDGAR |
| 2017-10-05 | — | Mixed | −45,661 | -$706.9K | |
| 2017-09-27 | Kite Pharma, Inc. (KITE) Delisted | Mixed | −3,739 | -$1.39M | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.